BPA #36E79722A0024 for flolan
Ended Awarded Last action
- Contract number
- 36E79722A0024
- Awardee
-
Glaxosmithkline, LLC UEI FRHTPHMZMX47
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $299,605.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
This Blanket Purchase Agreement (BPA) #36E79722A0024, awarded as a single award on September 1, 2022, establishes a supply contract for Flolan between the Department of Veterans Affairs National Acquisition Center and GlaxoSmithKline, LLC. The contract carries a ceiling value of $299,605.00 and operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The award includes no set-aside designation, indicating full and open competition at the time of solicitation. The BPA is scheduled for cancellation on December 31, 2025, marking the ultimate completion date for this indefinite delivery vehicle. GlaxoSmithKline, a pharmaceutical company headquartered in Durham, North Carolina, has been selected as the sole source vendor for this requirement, leveraging the company's established capabilities in pharmaceutical product delivery to federal agencies.
Flolan is a parenteral pharmaceutical product used primarily in the treatment of pulmonary arterial hypertension and represents a specialized medical countermeasure within the Department of Veterans Affairs' pharmaceutical procurement portfolio. This BPA enables the Veterans Affairs National Acquisition Center to efficiently manage and order Flolan supplies across the veteran healthcare system without requiring individual competitive procurements for each delivery order. The indefinite delivery structure allows the government to issue task orders as needed up to the contract ceiling, providing flexibility in managing inventory and fulfillment schedules while maintaining price certainty through the established BPA terms. GlaxoSmithKline's involvement in this contract reflects its critical role in supporting government healthcare delivery and its established performance history supplying specialized pharmaceuticals to federal healthcare systems.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Legal Contract Cancellation | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79722A0024?
36E79722A0024 was awarded to Glaxosmithkline, LLC by National Acquisition Center (Headquarters) on September 1, 2022.
How much is contract 36E79722A0024 worth?
36E79722A0024's own ceiling is $299,605.
Who can order from contract 36E79722A0024?
36E79722A0024 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79722A0024 under another contract?
Yes. 36E79722A0024 is a blanket purchase agreement under 36F79722D0178, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79722A0024 competed?
The extent of competition for 36E79722A0024 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV